Our findings may also signify potential cardiovascular side effects when using calcilytics in treating diseases such as osteoporosis and hypocalcaemia from gain-of-function CaSR mutations (Hebert, 2006, Jensen and Bräuner-Osborne, 2007, Saidak et al., 2009). This evidence concerns the gene CASR and osteoporosis.